



---

Year: 2013

---

**Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity(R) catheter system and the EnligHTN multi-electrode renal denervation catheter**

Templin, C; Jaguszewski, M; Ghadri, J R; Sudano, I; Gaehwiler, R; Hellermann, J P;  
Schoenenberger-Berzins, R; Landmesser, U; Erne, P; Noll, G; Luscher, T F

**Abstract:** AIMS: Catheter-based renal nerve ablation (RNA) using radiofrequency energy is a novel treatment for drug-resistant essential hypertension. However, the local endothelial and vascular injury induced by RNA has not been characterized, although this importantly determines the long-term safety of the procedure. Optical coherence tomography (OCT) enables in vivo visualization of morphologic features with a high resolution of 10-15 microm. The objective of this study was to assess the morphological features of the endothelial and vascular injury induced by RNA using OCT. **METHODS AND RESULTS:** In a prospective observational study, 32 renal arteries of patients with treatment-resistant hypertension underwent OCT before and after RNA. All pre- and post-procedural OCT pullbacks were evaluated regarding vascular changes such as vasospasm, oedema (notches), dissection, and thrombus formation. Thirty-two renal arteries were evaluated, in which automatic pullbacks were obtained before and after RNA. Vasospasm was observed more often after RNA than before the procedure (0 vs. 42%,  $P < 0.001$ ). A significant decrease in mean renal artery diameter after RNA was documented both with the EnligHTN (4.69 +/- 0.73 vs. 4.21 +/- 0.87 mm;  $P < 0.001$ ) and with the Simplicity(R) catheter (5.04 +/- 0.66 vs. 4.57 +/- 0.88 mm;  $P < 0.001$ ). Endothelial-intimal oedema was noted in 96% of cases after RNA. The presence of thrombus formations was significantly higher after the RNA than before ablation (67 vs. 18%,  $P < 0.001$ ). There was one evidence of arterial dissection after RNA with the Simplicity(R) catheter, while endothelial and intimal disruptions were noted in two patients with the EnligHTN catheter. **CONCLUSION:** Here we show that diffuse renal artery constriction and local tissue damage at the ablation site with oedema and thrombus formation occur after RNA and that OCT visualizes vascular lesions not apparent on angiography. This suggests that dual antiplatelet therapy may be required during RNA.

DOI: <https://doi.org/10.1093/eurheartj/eh141>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-84145>

Accepted Version

Originally published at:

Templin, C; Jaguszewski, M; Ghadri, J R; Sudano, I; Gaehwiler, R; Hellermann, J P; Schoenenberger-Berzins, R; Landmesser, U; Erne, P; Noll, G; Luscher, T F (2013). Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the

Simplicity(R) catheter system and the EnligHTN multi-electrode renal denervation catheter. *European Heart Journal*, 34(28):2141-2148.  
DOI: <https://doi.org/10.1093/eurheartj/eh141>

**Vascular Lesions induced by Renal Nerve Ablation as assessed by  
Optical Coherence Tomography -  
Pre- and postprocedural comparison with the Simplicity Catheter System<sup>®</sup> and  
the EnligHTN<sup>™</sup> Multi-Electrode Renal Denervation Catheter**

Christian Templin<sup>1\*</sup>, MD, PhD; Milosz Jaguszewski<sup>1\*</sup>, MD; Jelena R. Ghadri<sup>1</sup>, MD; Isabella Sudano<sup>1</sup>, MD; Roman Gaehwiler<sup>1</sup>; Jens P. Hellermann, MD, MSc<sup>3</sup>; Renate Schoenenberger-Berzins<sup>2</sup>, MD; Ulf Landmesser<sup>1</sup>, MD; Paul Erne<sup>2</sup>, MD; Georg Noll<sup>1</sup>, MD; Thomas F. Lüscher<sup>1</sup>, MD<sup>§</sup>

<sup>1</sup>Department of Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Department of Cardiology, Luzerner Kantonsspital, Switzerland and <sup>3</sup> Division of Cardiology, Altstätten Hospital, Switzerland

\*These authors contributed equally to this work

Total word count: ~~43763763~~

**§Corresponding author:**

Thomas F. Lüscher, MD, FRCP  
Professor and Chairman of Cardiology  
University Hospital of Zurich,  
Raemistrasse 100  
CH-8091 Zürich  
Phone: +41 (0)44 255 9585  
Fax: +41 (0)44 255 4401  
E-mail: [cardiotfl@gmx.ch](mailto:cardiotfl@gmx.ch)  
[www.tomluescher.ch](http://www.tomluescher.ch)

## Abstract

**Background:** Catheter-based renal nerve ablation (RNA) using radiofrequency energy is a novel treatment for drug-resistant essential hypertension. However, the local endothelial and vascular injury induced by RNA has not been characterized, although this importantly determines the long-term safety of the procedure. Optical coherence tomography (OCT) enables *in vivo* visualization of morphologic features with a high resolution of 10 to 15  $\mu\text{m}$ .

**Objective:** To assess the morphologic features of the endothelial and vascular injury induced by RNA using OCT

**Methods:** In a prospective observational study 32 renal arteries of patients with treatment-resistant hypertension underwent OCT before and after RNA. All pre- and post-procedural OCT pullbacks were evaluated regarding vascular changes such as vasospasm, oedema (notches), dissection and thrombus formation.

**Results:** Thirty-two renal arteries were evaluated, in which automatic pullbacks were obtained before and after RNA. Vasospasm was observed more often after RNA than before the procedure (0% vs. 42%,  $p < 0.001$ ). A significant decrease in mean renal artery diameter after RNA was documented both with the EnligHTN<sup>TM</sup> ( $4.69 \pm 0.73\text{mm}$  vs.  $4.21 \pm 0.87\text{mm}$ ;  $p < 0.001$ ) and Simplicity<sup>®</sup> catheter ( $5.04 \pm 0.66\text{mm}$  vs.  $4.57 \pm 0.88\text{mm}$ ;  $p < 0.001$ ). Endothelial-intimal oedema was noted in 96% of cases after RNA. The presence of thrombus formations was significantly higher after the RNA than before ablation (67% vs. 18%,  $p < 0.001$ ). There was one evidence of arterial dissection after RNA with the Simplicity<sup>®</sup> catheter, while endothelial and intimal disruption was noted in 2 patients with the EnligHTN<sup>TM</sup> catheter.

**Conclusions:** Here we show that diffuse renal artery constriction and local tissue damage at the ablation site with oedema and thrombus formation occurs after RNA and that OCT visualizes vascular lesions not apparent on angiography. This suggests that platelet inhibition may be required during RNA.

## Introduction

Today approximately one billion people are affected by arterial hypertension.<sup>1-5</sup> Data of the World Health Organization suggest that one in three adults suffer from elevated blood pressure resulting in a worldwide socioeconomic health problem. Indeed, the link between high blood pressure and increased cardiovascular morbidity and mortality is well established.<sup>6-8</sup> Despite the availability and use of different classes of antihypertensive drugs, 5-30% of patients still show elevated blood pressure.<sup>9-12</sup>

Blood pressure is regulated by the sympathetic nervous system, hormonal and endothelial factors as well as renal water and sodium handling. The kidney is innervated by efferent and afferent sympathetic nerves regulating renal vascular resistance and renin release.<sup>13</sup> Recently, a novel catheter-based radiofrequency ablation technique has been developed allowing for renal nerve ablation (RNA) with a very low complication rate and without major side effects.<sup>14</sup> Registry data and small randomized trials have shown that RNA effectively lowers blood pressure in patients with treatment resistant hypertension. Currently, two different catheter based systems are primarily used.<sup>15-17</sup> The Simplicity Catheter System<sup>®</sup> by Medtronic-Adrian is a sequential denervation system allowing for delivery of low-power radiofrequency energy of 5-8 W at several sites within the renal artery. The EnligHTN<sup>™</sup> multi-electrode RNA catheter from St. Jude Medical consists of a multi-ablation basket with an integrated 4 point contact surface to deliver radiofrequency energy. However, data regarding the local vascular injury induced by the radiofrequency energy are lacking. This is of importance for the long-term safety of the procedure, particularly since recently the development of a renal artery stenosis after RNA has been reported.<sup>18</sup>

Optical coherence tomography (OCT) has been established as an intracoronary imaging tool visualizing stent apposition and healing, plaque characterization, thrombus formation, and dissection with a high spatial resolution of 10 to 15  $\mu\text{m}$ <sup>19</sup> which is approximately 10-fold higher than intravascular-ultrasound (IVUS).<sup>20</sup> Therefore, the aim of the present study was to evaluate the morphologic features before and after renal ablation by OCT prospectively.

## 1 **Methods**

2

### 3 **Patient Population**

4 This is a prospective observational double-center study conducted at the University Hospital  
5 of Zurich and Cantonal Hospital of Lucerne, Switzerland. Individuals were eligible for the  
6 study if they were >18 years and had primary and idiopathic cause of resistant arterial  
7 hypertension defined as persistent systolic blood pressure >160mmHg, with at least  
8 established 3 antihypertensive medication (including diuretics) or patients with allergies to  
9 antihypertensive drugs. All patients were on daily aspirin 100 mg or received 250 – 500 mg  
10 aspirin intravenously before starting the renal nerve ablation procedure. One patient was on  
11 single clopidogrel treatment because of in-stent thrombosis in the past after myocardial  
12 infarction. No patient was on dual antiplatelet therapy at the time of the procedure.

13 Patients were excluded from the study, if glomerular filtration rate (GFR) was <45ml/min.

14 Sixteen consecutive patients were included and thirty-two renal arteries were accurately  
15 evaluated. All patients underwent renal nerve ablation (RNA) with the Simplicity Catheter  
16 System<sup>®</sup> by Medtronic-Adrian or the EnligHTN<sup>™</sup> multi-electrode by St. Jude Medical  
17 according to the operator's discretion. All patients provided written informed consent before  
18 the procedure to participate in the present study.

19

### 20 **Catheter-Based Renal Denervation Procedure**

21 The RNA procedure with the Simplicity<sup>®</sup> system (Medtronic, Minneapolis, USA) consists of  
22 a catheter-based approach to disrupt renal sympathetic nerves using radiofrequency energy  
23 (1 Watt) applied to the renal artery via an electrode at the catheter tip. The catheter was  
24 placed in the distal lumen of the main renal artery using a 6F guide via a femoral artery  
25 access site. Then the catheter was retracted sequentially by 5mm each and rotated  
26 circumferentially before energy was delivered. A total of 6 to 8 ablations of 2 minute duration  
27 were applied in each renal artery including the complete circumference of the vessel.

28 RNA with the EnligHTN<sup>™</sup> multi-electrode renal denervation ablation catheter (St. Jude  
29 Medical Inc., Westford, USA) involves a basket with multiple ablation surface points. The

1 catheter was placed in the distal lumen of the main renal artery using a 6F guide and four  
2 ablations were set sequentially in 90-seconds intervals. Afterwards a minimal catheter  
3 repositioning was performed and the procedure repeated more proximally.

4

#### 5 **Optical Coherence Tomography**

6 All patients underwent OCT utilizing the C7-XR imaging system (LightLab Imaging, Inc.,  
7 Westford, USA) before and after renal denervation. OCT images were performed by using a  
8 non-occlusive acquisition technique and a single-mode optical fibre catheter (frequency  
9 domain-OCT-catheter, DragonFly™, St. Jude Medical, Westford, USA). In each renal artery,  
10 routinely two pullbacks were obtained pre- and post-renal nerve ablation. The OCT catheter  
11 was advanced over a conventional 0.014” angioplasty guide wire using a monorail lumen at  
12 the tip. Renal arteries were flushed of blood with Ultravist 300 (Bayer House, Berkshire,  
13 United Kingdom) at a flow rate of 8.0 ml/s. The automated pullback and contrast injection  
14 was obtained in all patients to optimize the image quality. The acquisition sequence speed  
15 was 20 mm/second.

16

#### 17 **Optical Coherence Tomography Evaluation**

18 OCT pullbacks were analyzed in a teaching core laboratory of the Andreas Gruentzig-  
19 Catheterization Laboratory at the University Hospital of Zurich, Switzerland by two  
20 independent investigators blinded to the clinical and procedural characteristics of the  
21 patients, using a proprietary software (LightLab Imaging). Image quality was assessed for all  
22 OCT images using a four point scale (excellent, good, moderate, non-diagnostic, artefact). In  
23 the presence of disagreement between the two observers, a consensus agreement was  
24 made. All pre- and post-procedural pullbacks were evaluated for local acute morphological  
25 vascular changes such as vasospasm, dissections, wall oedemas (vessel notches) and  
26 thrombus formations. Lumen and cross-section-areas were drawn at 3 mm intervals and  
27 calculated as appropriate. Automatic detection of mean diameter was manually corrected  
28 frame by frame.

29

1 **Lesion Characterization by Optical Coherence Tomography**

2 Oedema was defined as any significant endothelial-intimal notch detected on the luminal  
3 wall surface. Vasospasm was defined by immediate loss of lumen area or lumen diameter in  
4 any part of renal artery. Endothelial or intimal disruptions of the superficial intimal lining were  
5 defined as endothelial detachments or vessel dissections. Intraluminal thrombus was defined  
6 as a protruding mass attached to the luminal surface with a diameter of  $\geq 0.5$  mm in at least 3  
7 following cross-sections.

8

9 **Statistical Analysis**

10 Baseline characteristics are summarized using frequency tables with count and proportion for  
11 each category, or mean and standard deviation (SD) as appropriate. All data were checked  
12 by means of Shapiro-Wilk-W test for normal distribution. We then performed paired t-test for  
13 the pre- post comparisons for continuous variables. McNemars Test was used for nominal  
14 variables.

15 SPSS software (Chicago, Illinois; Version 20.0) was used for all statistical analysis. A two  
16 tailed p-value  $\leq 0.05$  was considered as statistical significant. Data are shown as  
17 percentages.

18



## 1 **Results**

2

### 3 **Baseline Characteristics**

4 Sixteen patients were included based on image quality in the final analysis, 9 males and 7  
5 females. The average age was  $58.5 \pm 9.9$  years. All patients had drug-resistant hypertension  
6 ( $n=14$ ) or intolerance and/or allergy towards antihypertensive agents ( $n=2$ ). Of all patients  
7 included into the study, 56% had dyslipidemia ( $n=9$ ), 19% diabetes mellitus ( $n=3$ ), 56%  
8 obesity ( $n=9$ ), and 38% were current smoker at the time of inclusion ( $n=6$ ). 25% had known  
9 coronary artery disease (CAD) or a stroke ( $n=4$ ). The average number of antihypertensive  
10 drugs was  $3.8 \pm 1.1$ . Drugs on admission, laboratory values and baseline characteristics are  
11 shown in **Table 1**.

12

### 13 **Optical Coherence Tomography Evaluation**

14 In total 32 renal arteries were evaluated, in which two automatic pullbacks had been  
15 obtained before and after RNA. Forty four pullbacks were performed before and after RNA  
16 with the Simplicity<sup>®</sup> catheter and twenty with the EnligHTN<sup>™</sup> catheter. Only good-to-excellent  
17 quality pullbacks were included into the final analysis. The study flow chart is presented in  
18 **Figure 1**. Pullbacks with poor-to-moderate quality ( $n=16$ , with Simplicity<sup>®</sup> catheter;  $n=2$ , with  
19 EnligHTN<sup>™</sup> catheter) were excluded from the analysis. 548 cross-sections with an excellent  
20 quality were drawn to calculate lumen diameters.

21

### 22 **Vascular Spasm**

23 We observed vasospasm in 10 renal arteries (42%) after RNA and no before the procedure  
24 ( $p<0.001$ ) (**Table 2**). Vessel spasm was encountered along the entire length of the treated  
25 artery resulting in a significant reduction of the mean renal artery diameter after the  
26 procedure. The mean renal artery diameter before and after the procedure was  $4.84 \pm 0.72$   
27 mm vs.  $4.37 \pm 0.89$  mm ( $p<0.001$ ). The difference between mean diameter before and after  
28 RNA was significant in both groups with the EnligHTN<sup>™</sup> catheter ( $4.69 \pm 0.73$  mm vs.  $4.21 \pm$

1 0.87 mm,  $p < 0.001$ ) and the Simplicity<sup>®</sup> catheter ( $5.04 \pm 0.66$  mm vs.  $4.57 \pm 0.88$  mm,  
2  $p < 0.001$ ) (**Figure 2 and 3**).

3

#### 4 Oedema

5 The OCT cross-sections showed angiographically inapparent prominent vessel notches at  
6 the sites where radiofrequency-derived energy had been delivered (**Figure 4**). We  
7 documented the presence of endothelial-intimal oedema in all patients after renal  
8 denervation with the Simplicity<sup>®</sup> catheter ( $n=15$ ) and in 89% after using the EnligHTN<sup>™</sup>  
9 catheter ( $n=8$ ). However, not all ablations points (4-11 per renal artery) resulted in a similar  
10 degree of notch formation as documented by OCT. We notified 72 notches in all 24 pullbacks  
11 performed after the RNA procedure. The mean amount of vessel notches before and after  
12 RNA was  $0.58 \pm 0.83$  and  $3.0 \pm 2.0$ , respectively ( $p < 0.001$ ).

13

#### 14 Thrombus Formation

15 We found the evidence of intraluminal thrombus formation more often after renal nerve  
16 ablation than before the procedure (67% vs. 18%,  $p < 0.001$ ) (**Table 2, Figure 5**), 64 thrombi  
17 were documented during all pullbacks after RNA and only 8 before the procedure. Also the  
18 mean amount of thrombus formations measured per renal artery was significantly higher after  
19 the procedure ( $2.67 \pm 2.76$  vs.  $0.33 \pm 0.87$ ,  $p < 0.001$ ).

20

#### 21 Dissection

22 We have documented five arterial dissections/disruptions after RNA in three renal arteries.  
23 (**Table 2, Figure 6**).

24

#### 25 Comparison of two catheter-based systems used in our study: EnligHTN<sup>™</sup> versus Simplicity<sup>®</sup>

26

27 There was no significant difference in the amount of oedema between the Simplicity<sup>®</sup> and the  
28 EnligHTN<sup>™</sup> catheter measured per renal artery ( $3.1 \pm 1.9$  vs.  $2.3 \pm 2.0$ ,  $p = 0.35$ ). We did not  
29 notified also any differences after the Simplicity<sup>®</sup> catheter and the EnligHTN<sup>™</sup> catheter

1 regarding the vessel spasm (40% vs. 44%,  $p=0.83$ ). We have documented one evidence of  
2 arterial dissection after renal ablation with the Simplicity<sup>®</sup> catheter, while endothelial and  
3 intimal disruption was observed in 2 patients after the EnligHTN<sup>™</sup> catheter use ( $p=0.26$ ;  
4 **Figure 6**).

5 However we observed a trend towards the intraluminal thrombus formation, i.e. in 89% of  
6 the cases using the EnligHTN<sup>™</sup> catheter and in 53% with the Simplicity<sup>®</sup> catheter-based  
7 basket ablation system ( $p=0.07$ ). Moreover, a significantly greater thrombus load per renal  
8 artery was observed after RNA with the EnligHTN<sup>™</sup> system compared to the Simplicity<sup>®</sup>  
9 system ( $4.6 \pm 3.1$  vs.  $1.5 \pm 1.8$ ,  $p=0.006$ ).

10

11

12

## Discussion

This is the first study to evaluate prospectively the morphologic features of RNA induced renal vascular injury by OCT in patients before and after renal denervation using two different catheter systems, i.e. the Simplicity<sup>®</sup> Catheter and the EnligHTN<sup>™</sup> multi-electrode basket. While the feasibility and effectiveness in reducing blood pressure have been documented in registries and randomized trials using the Simplicity Catheter System<sup>®16, 17</sup> and to a lesser degree with the EnligHTN<sup>™</sup> multi-electrode basket, little is known about the vascular injury induced by the RNA procedure at the site of ablation. We here for the first time demonstrate with OCT that local tissue damage not apparent with angiography occurs, i.e. local and diffuse vasospasm, oedema formation and endothelial injury with thrombus generation.

An initial observation revealed that catheter-based RNA could be complicated by vascular lesions, i.e. vessel notches, post-procedural vasospasm, dissections and thrombus formations. Moreover, with the EnligHTN<sup>™</sup> multi-electrode system more thrombus formation per renal artery occurred than with the Simplicity Catheter System<sup>®</sup>.

In this regard, recent animal studies are of interest demonstrating local loss of the endothelial monolayer resulting in thrombus formation even at 6 month follow-up.<sup>21,22</sup> These observations in patients and animal models suggest that an antithrombotic therapy should be used before and after RNA, possibly for prolonged periods of time. This notion is further supported by the fact that renal artery stenosis may indeed occur after RNA, possibly evolving from such injuries.<sup>18</sup>

In contrast to Steigerwald, we have observed one dissection after RNA in our series with the Simplicity Catheter System<sup>®</sup>.<sup>22</sup> In this regard one patient of the Simplicity<sup>®</sup> HTN-1 study developed also renal artery dissection.<sup>23</sup> Of note, the true incidence of renal artery dissection could be markedly underestimated in the Simplicity<sup>®</sup> HTN-1 study, since no intravascular imaging was performed in these patients.

Local notches, which are signs of vessel wall oedema, occurred after RNA with both catheter systems without statistically significant difference between the two. Based on histological analyses of a preclinical study, notches correspond to cellular swelling and

1 connective tissue coagulation within the medial and adventitial layer.<sup>22</sup> This formation of local  
2 oedema with water retention within the ablated tissue and an inflammatory response is also  
3 known from electrophysiological studies in which radiofrequency ablation is used. It is  
4 assumed that such oedemas are only present in the acute phase immediately after RNA and  
5 therefore a transient phenomenon of inflammation.<sup>21</sup> Possibly, local oedema may reflect  
6 effective renal denervation. Obviously, whether the larger tissue damage really leads to a  
7 more effective decrease in blood pressure needs to be elucidated. Furthermore, it is unclear  
8 whether the presence of a concomitant atherosclerotic disease in renal arteries has an  
9 impact on the success of RNA on arterial blood pressure.

10 A three-dimensional OCT image reconstruction documented a circumscribed vascular  
11 spasm for both catheter systems leading to a “pearl-of-string” feature with significant  
12 reduction in the mean renal artery diameter as well after RNA. Obviously renal vasospasm  
13 can also result from catheter manipulation by the operator; however, the “pearl-of-string”  
14 pattern (encountered along the entire length of the treated renal artery) strongly suggests  
15 that such a generalized vasospasm of treated renal arteries most likely results from the  
16 mechanical stress induced by the ablation catheter tip or basket, respectively and/or the  
17 applied radiofrequency energy itself rather than from catheter manipulation. The mechanism  
18 of such a diffuse vasoconstriction not only at the site of ablation remains unknown, but may  
19 involve a reduced nitric oxide release after endothelial damage. However, in the experience  
20 of most operators, nitrates and calcium antagonists are not very effective in this context.  
21 Possibly, endothelin release, which leads to prolonged vasospasm, may be involved.<sup>24</sup>

22

### 23 **Limitations**

24 It is a limitation of this study that a rather small number of patients has yet been studied and  
25 thus these results have to be confirmed in a larger patient population. The comparison of  
26 both catheter-based systems is observational and selection bias could have occurred.  
27 However, the selection of the system was done by an independent study coordinator who  
28 was not involved in the RNA procedure, which would help to alleviate concerns of obvious  
29 selection bias. Further, the maximal field of view in OCT is limited to 11 mm, therefore

1 patients with large renal artery diameter are difficult to study. Moreover, imaging depth is  
2 limited to 0.5-2.0 mm with OCT. Therefore, renal arteries with thick walls cannot be properly  
3 evaluated in their entirety. The number of pullbacks excluded due to poor quality is much  
4 higher with the Simplicity system as compared to the EnligHTN system. This reflects the real  
5 world practice for which reason we have not excluded the failed cases from our enrolment.  
6 However, the imbalance in excluded data could impair the validity of the analysis.  
7 Furthermore, no renal artery flows measurements with renal duplex-sonography before and  
8 after RNA was performed.

## 10 **Conclusions**

11 This study for the first time demonstrates that renal artery OCT is feasible in most patients  
12 before and after RNA and useful to depict acute vascular injury after the procedure. OCT  
13 after RNA allows for a better understanding of the local vascular injury induced by different  
14 ablation systems. Indeed, this first experience suggests that the EnligHTN™ multi-electrode  
15 basket induces a different tissue response with a higher amount of thrombus formation  
16 measured per renal artery than the Simplicity® catheter. Larger studies with short- and long-  
17 term follow-up by OCT now need to further document the type and extent of the healing  
18 response after RNA and the relation between local injury and the blood pressure response  
19 after the procedure. Based on our findings, we recommend to perform OCT routinely in  
20 patients after RNA and to effectively inhibit platelet activation with either acetylsalicylic acid  
21 or an ADP-receptor antagonist.

## 24 **Conflict of Interest**

25 The institution of the authors has received educational and research grants from Medtronic,  
26 Tollachenaz, Switzerland and St. Jude Medical, Brussels, Europe. TFL has received  
27 consultant honoraria from both companies.

1 **Tables**

2

**Table 1.** Baseline Characteristics

	<i>All patients (n=16)</i>	<i>Simplicity<sup>®</sup> (n=11)</i>	<i>EnligHTN<sup>™</sup> (n=5)</i>	<i>P value</i>
Age (years), mean (±SD)	58.5 (±9.9)	58.3 (±8.7)	59.0 (±13.7)	0.90
Male gender, n (%)	9 (56)	6 (55)	3 (60)	0.84
<b>Cardiovascular risk factors, n (%)</b>				
Arterial hypertension	16 (100)	11 (100)	5 (100)	1.00
Dyslipidemia	9 (56)	6 (55)	3 (60)	0.84
Current smoker	6 (38)	5 (45)	1 (20)	0.33
Diabetes mellitus	3 (19)	2 (18)	1 (20)	0.93
Obesity	9 (56)	5 (45)	4 (80)	0.20
<b>Cardiovascular history, n (%)</b>				
Known CAD or Stroke	4 (25)	4 (36)	0	0.12
<b>Laboratory values, mean (±SD)</b>				
Creatinine before RNA, (µmol/l)	78.5 (±16.5)	77.2 (±20.3)	81.4 (±5.7)	0.65
Creatinine after RNA, (µmol/l)	84.5 (±23.8)	87.1 (±28.4)	79.4 (±11.9)	0.57
<b>Medication, n (%)</b>				
ACE inhibitor	5 (31)	5 (45)	0	0.07
ARB	12 (75)	8 (73)	4 (80)	0.76
Beta-blocker	12 (75)	9 (82)	3 (60)	0.35
Calcium-channel blocker	10 (63)	6 (55)	4 (80)	0.33
Diuretics	13 (81)	9 (82)	4 (80)	0.93
Statins	8 (50)	6 (55)	2 (40)	0.59
Sum of medications per patient, mean (±SD)	3.8 (±1.1)	3.9 (±0.9)	3.4 (±1.7)	0.44
No. of patients with drug intolerance/allergy, n	2 (13)	1 (9)	1 (20)	0.54

Abbreviations: ACE=angiotensin-converting enzyme; ARB=angiotensin-receptor blocker; CAD, coronary artery disease; RNA= renal nerve ablation

3  
4  
5  
6  
7  
8  
9  
10  
11

1  
2



1  
2  
3

**Table 2.** OCT findings before and after RNA

	Before RNA, pullbacks (n=22)	After RNA, pullbacks (n=24)	P value
Oedema, n pullbacks (%)	10 (45)	23 (96)	<0.001
Oedema in total	14	72	
Oedema per RA	0.58±0.83	3.0±2.0	<0.001
Thrombus, n pullbacks (%)	4 (18)	16 (67)	<0.001
Thrombi in total	8	64	
Thrombi per RA	0.33±0.87	2.67±2.76	<0.001
Vasospasm, n pullbacks (%)	0	10 (42)	<0.001
Vasospasm in total	0	18	
Vasospasm per RA	0	0.75±1.07	0.0013
Dissection/Tissue Disruption, n pullbacks (%)	0	3 (13)	0.086
Dissection/Tissue Disruption in total	0	5	
Dissection per RA	0	0.21±0.59	0.09

Abbreviation: RA=renal artery; RNA= renal nerve ablation

1 **Figure Legend**

2

3 **Figure 1: Study flow chart**

4

5 **Figure 2: Changes of vessel diameter after renal nerve ablation**

6 Significant differences of vessel diameters before and after renal nerve ablation were  
7 observed with both, the EnligHTN™ (St. Jude Medical) and the Simplicity® (Medtronic)  
8 catheter. Vessel spasm was documented along the whole length of the treated artery.

9

10 **Figure 3: Vasospasm of renal arteries after renal nerve ablation**

11 Right renal artery (A-E) and left renal artery (F-J). Baseline angiography (A and F) and OCT  
12 imaging (B and G) before renal artery ablation with the EnligHTN™ catheter. Vasospasm  
13 observed after radiofrequency therapy with both angiography (C and H) and OCT (D and I).  
14 Three-dimensional OCT reconstruction of right and left renal artery after renal denervation (E  
15 and J).

16

17 **Figure 4: Vessel wall oedemas after after renal nerve ablation**

18 Renal artery before (A) and after (B) Simplicity® catheter based renal denervation. Direct  
19 after ablation vessel notches are inapparent in angiography (B) and discernible at the lesion  
20 site by OCT imaging (C, frame and D).

21

22 **Figure 5: Thrombus formation after renal nerve ablation**

23 Significant intraluminal thrombus formation after renal nerve denervation are inapparent in  
24 angiography (A and D), however displayed in different OCT cross-sections (B, C, E, F and I)  
25 and in three-dimensional reconstructed renal artery (G and H).

26

27 **Figure 6: Dissections after renal nerve ablation**

28 Endothelial detachments (A, white box) and vessel wall dissections (B, red arrow) detected in  
29 treated renal arteries with the EnligHTN™ catheter.

## 1   **References**

- 2
- 3   1.     Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden  
4         of hypertension: Analysis of worldwide data. *Lancet*. 2005;**365**:217-223.
- 5   2.     Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J,  
6         Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S.  
7         Effects of different regimens to lower blood pressure on major cardiovascular events  
8         in older and younger adults: Meta-analysis of randomised trials. *BMJ*. 2008;**336**:1121-  
9         1123.
- 10  3.     Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of  
11         usual blood pressure to vascular mortality: A meta-analysis of individual data for one  
12         million adults in 61 prospective studies. *Lancet*. 2002;**360**:1903-1913.
- 13  4.     Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related  
14         disease, 2001. *Lancet*. 2008;**371**:1513-1518.
- 15  5.     Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova  
16         R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G,  
17         Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K,  
18         Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE,  
19         Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of  
20         european guidelines on hypertension management: A european society of  
21         hypertension task force document. *J Hypertens*. 2009;**27**:2121-2158.
- 22  6.     Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and  
23         cardiovascular risks. Us population data. *Arch Intern Med*. 1993;**153**:598-615.
- 24  7.     Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment.  
25         *JAMA*. 1996;**275**:1571-1576.
- 26  8.     Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in  
27         mortality from cardiovascular disease. The framingham heart study. *N Engl J Med*.  
28         1990;**322**:1635-1641.

- 1 9. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras  
2 A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified  
3 on the basis of ambulatory blood pressure monitoring. *Hypertension*. 2011;**57**:898-  
4 902.
- 5 10. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman  
6 WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant  
7 hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the  
8 american heart association professional education committee of the council for high  
9 blood pressure research. *Hypertension*. 2008;**51**:1403-1419.
- 10 11. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, Reiner Z,  
11 Gaita D, Wood D, Kotseva K, Heidrich J. Blood pressure control and knowledge of  
12 target blood pressure in coronary patients across europe: Results from the euroaspire  
13 iii survey. *J Hypertens*. 2011;**29**:1641-1648.
- 14 12. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and  
15 apparent treatment resistant hypertension in the united states, 1988 to 2008.  
16 *Circulation*. 2011;**124**:1046-1058.
- 17 13. DiBona GF, Kopp UC. Neural control of renal function. *Physiol Rev*. 1997;**77**:75-197.
- 18 14. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G,  
19 Ruilope L, van de Borne P, Tsioufis C. Esh position paper: Renal denervation - an  
20 interventional therapy of resistant hypertension. *J Hypertens*. 2012;**30**:837-841.
- 21 15. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal  
22 denervation as a therapeutic approach for hypertension: Novel implications for an old  
23 concept. *Hypertension*. 2009;**54**:1195-1201.
- 24 16. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B,  
25 Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal  
26 sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-  
27 principle cohort study. *Lancet*. 2009;**373**:1275-1281.

- 1 17. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal  
2 sympathetic denervation in patients with treatment-resistant hypertension (the  
3 simplicity htn-2 trial): A randomised controlled trial. *Lancet*. 2010;**376**:1903-1909.
- 4 18. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog SC. Renal  
5 artery stenosis after renal sympathetic denervation. *J Am Coll Cardiol*. 2012;**60**:2694-  
6 2695.
- 7 19. Templin C, Meyer M, Muller MF, Djonov V, Hlushchuk R, Dimova I, Flueckiger S,  
8 Kronen P, Sidler M, Klein K, Nicholls F, Ghadri JR, Weber K, Paunovic D, Corti R,  
9 Hoerstrup SP, Luscher TF, Landmesser U. Coronary optical frequency domain  
10 imaging (ofdi) for in vivo evaluation of stent healing: Comparison with light and  
11 electron microscopy. *Eur Heart J*. 2010;**31**:1792-1801.
- 12 20. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte  
13 T, Gregory K, Puliafito CA, et al. Optical coherence tomography. *Science*.  
14 1991;**254**:1178-1181.
- 15 21. Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal  
16 sympathetic denervation: Chronic preclinical evidence for renal artery safety. *Clin Res*  
17 *Cardiol*. 2011;**100**:1095-1101.
- 18 22. Steigerwald K, Titova A, Malle C, Kennerknecht E, Jilek C, Hausleiter J, Nahrig JM,  
19 Laugwitz KL, Joner M. Morphological assessment of renal arteries after  
20 radiofrequency catheter-based sympathetic denervation in a porcine model. *J*  
21 *Hypertens*. 2012;**30**:2230-2239.
- 22 23. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of  
23 blood pressure reduction out to 24 months. *Hypertension*. 2011;**57**:911-917.
- 24 24. Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, Luscher TF.  
25 Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine  
26 and serotonin in human arteries. A new mechanism of vasospasm? *Circulation*.  
27 1990;**82**:188-195.

28

29